Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:epilepsy
|
| gptkbp:advocacy |
policy changes
public awareness campaigns increased funding |
| gptkbp:affects |
cognitive impairment
increased risk of sudden death |
| gptkbp:associated_with |
SCN1 A gene mutation
|
| gptkbp:cause |
severe seizures
|
| gptkbp:clinical_trial |
ongoing
investigating gene therapy investigating cannabinoids investigating new medications |
| gptkbp:community |
support groups available
|
| gptkbp:community_health |
sleep disorders
anxiety disorders attention deficit hyperactivity disorder autism spectrum disorder |
| gptkbp:diagnosis |
genetic testing
clinical evaluation |
| gptkbp:difficulty_levels |
high
|
| gptkbp:first_described_by |
Charlotte Dravet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dravet syndrome
|
| gptkbp:impact |
social isolation
educational challenges family stress |
| gptkbp:is_a_basis_for |
autosomal dominant inheritance
|
| gptkbp:management |
multidisciplinary approach
|
| gptkbp:outcome |
variable prognosis
lifelong condition need for ongoing care potential for improvement with age risk of comorbidities increases with age |
| gptkbp:premiered_on |
infancy
6 months to 18 months |
| gptkbp:prevalence |
1 in 15,700 births
|
| gptkbp:public_awareness |
Dravet Syndrome Foundation
|
| gptkbp:research |
ongoing
|
| gptkbp:research_focus |
patient registries
genetic counseling new therapies |
| gptkbp:support |
gptkb:financial_assistance
gptkb:educational_resources respite care services medical resources parent training programs |
| gptkbp:symptoms |
temperature sensitivity
behavioral issues developmental delays |
| gptkbp:treatment |
ketogenic diet
vagus nerve stimulation antiepileptic drugs |
| gptkbp:trigger_type |
illness
fever vaccination |
| gptkbp:bfsParent |
gptkb:Zygel
|
| gptkbp:bfsLayer |
6
|